Monte Rosa Therapeutics has finalized a global exclusive license agreement with Novartis to develop VAV1-directed molecular glue degraders, including MRT-6160. Novartis will handle all clinical development, starting with Phase 2 studies, while Monte Rosa will continue its Phase 1 study. The deal includes an upfront payment of $150 million and potential milestone payments totaling up to $2.1 billion, alongside shared profits from U.S. commercialization.
Novartis has entered a $150 million deal with Monte Rosa Therapeutics to develop molecular glue degraders targeting the immune signaling protein VAV1, which is considered "undruggable." The partnership could yield up to $2.1 billion in additional payments based on development milestones. Monte Rosa will complete the ongoing Phase 1 study of MRT-6160, while Novartis will manage further development, with both companies sharing profits and losses from commercialization.
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.